**Supplementary Table 1:** Number (%) of respondents for each level within the components of the EQ5D5L amongst survivors at 180 days

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **EQ-5D-5L Component** | **Europe** | | **India** | |
|  | 12 mg (n=224) | 6 mg (n=195) | 12 mg (n=98) | 6 mg  (n=98) |
| **Mobility** |  |  |  |  |
| * 1 (no problems) | 90 (44.6%) | 73 (40.6%) | 90 (91.8%) | 82 (85.4%) |
| * 2 (slight problems) | 53 (26.2%) | 43 (23.9%) | 6 (6.1%) | 10 (10.4%) |
| * 3 (moderate problems) | 39 (19.3%) | 37 (20.6%) | 1 (1.0%) | 4 (4.2%) |
| * 4 (severe problems) | 16 (7.9%) | 22 (12.2%) | 0 (0.0%) | 0 (0.0%) |
| * 5 (unable to walk around) | 4 (2.0%) | 5 (2.8%) | 1 (1.0%) | 0 (0.0%) |
| **Self-care** |  |  |  |  |
| * 1 (no problems with washing or dressing) | 159 (78.7%) | 144 (80.0%) | 89 (90.8%) | 85 (88.5%) |
| * 2 (slight problems) | 23 (11.4%) | 19 (10.6%) | 8 (8.2%) | 6 (6.2%) |
| * 3 (moderate problems) | 11 (5.4%) | 12 (6.7%) | 0 (0.0%) | 5 (5.2%) |
| * 4 (severe problems) | 2 (1.0%) | 3 (1.7%) | 0 (0.0%) | 0 (0.0%) |
| * 5 (unable to wash or dress) | 7 (3.5%) | 2 (1.1%) | 1 (1.0%) | 0 (0.0%) |
| **Usual activities** |  |  |  |  |
| * 1 (no problems with usual activities) | 65 (32.3%) | 68 (37.8%) | 92 (93.9%) | 83 (86.5%) |
| * 2 (slight problems) | 65 (32.3%) | 47 (26.1%) | 4 (4.1%) | 8 (8.3%) |
| * 3 (moderate problems) | 44 (21.9%) | 47 (26.1%) | 1 (1.0%) | 5 (5.2%) |
| * 4 (severe problems) | 13 (6.5%) | 16 (8.9%) | 0 (0.0%) | 0 (0.0%) |
| * 5 (unable to perform) | 14 (7.0%) | 2 (1.1%) | 1 (1.0%) | 0 (0.0%) |
| **Pain/discomfort** |  |  |  |  |
| * 1 (no pain or discomfort) | 84 (41.6%) | 73 (40.6%) | 84 (85.7%) | 71 (74.0%) |
| * 2 (slight) | 58 (28.7%) | 52 (28,9%) | 10 (10.2%) | 24 (25.0%) |
| * 3 (moderate) | 43 (21.3%) | 33 (18,3%) | 2 (2.0%) | 0 (0.0%) |
| * 4 (severe) | 16 (7.9%) | 19 (10.6%) | 1 (1.0%) | 1 (1.0%) |
| * 5 (extreme pain or discomfort) | 1 (0.5%) | 3 (1.7%) | 1 (1.0%) | 0 (0.0%) |
| **Anxiety/depression** |  |  |  |  |
| * 1 (no anxiety or depression) | 130 (64.7%) | 98 (54.4%) | 86 (87.8%) | 81 (84.4%) |
| * 2 (slight) | 42 (20.9%) | 46 (25.6%) | 10 (10.2%) | 10 (10.4%) |
| * 3 (moderate) | 23 (11.4%) | 25 (13.9%) | 1 (1.0%) | 3 (3.1%) |
| * 4 (severe) | 4 (2.0%) | 9 (5.0%) | 0 (0.0%) | 2 (2.1%) |
| * 5 (extremely anxious or depressed | 2 (1.0%) | 2 (1.1%) | 1 (1.0%) | 0 (0.0%) |

**Full list of COVID-STEROID 2 Collaborators**

|  |  |
| --- | --- |
| Marie W. Munch MD; | [marie.warrer.munch@regionh.dk](about:blank) |
| Sheila N. Myatra PhD; | [sheila150@hotmail.com](about:blank) |
| Bharath Kumar Tirupakuzhi Vijayaraghavan MD; | [bharath@icuconsultants.com](about:blank) |
| Sanjith Saseedharan MD, | [docsanjith@rediffmail.com](about:blank) |
| Thomas Benfield PhD; | [Thomas.Lars.Benfield@regionh.dk](about:blank) |
| Rebecka R. Wahlin PhD; | [rebecka.rubenson-wahlin@sll.se](about:blank) |
| Bodil S. Rasmussen PhD; | [bodil.steen.rasmussen@rn.dk](about:blank) |
| Anne Sofie Andreasen PhD; | [anne.sofie.andreasen@regionh.dk](about:blank) |
| Lone M. Poulsen MD, | [lmp@regionsjaelland.dk](about:blank) |
| Luca Cioccari MD; | [luca.cioccari@insel.ch](about:blank) |
| Mohd S. Khan MD; | [drsaif2k2@gmail.com](about:blank) |
| Farhad Kapadia MD; | [fnkapadia@gmail.com](about:blank) |
| Jigeeshu V. Divatia MD; | [jdivatia@yahoo.com](about:blank) |
| Anne C. Brøchner PhD; | [anne.craveiro.broechner@rsyd.dk](about:blank) |
| Morten H. Bestle PhD; | [Morten.Bestle@regionh.dk](about:blank) |
| Marie Helleberg PhD; | [Marie.Helleberg@regionh.dk](about:blank) |
| Jens Michelsen PhD; | [Jens.Michelsen3@rsyd.dk](about:blank) |
| Ajay Padmanaban MD; | [ajay@icuconsultants.com](about:blank) |
| Neeta Bose MD; | [neetabosenayak@hotmail.com](about:blank) |
| Anders Møller PhD; | [anmoe@regionsjaelland.dk](about:blank) |
| Kapil Borawake MD; | [drkapilb@gmail.com](about:blank) |
| Klaus T. Kristiansen MD; | [klaus.tjelle.kristiansen.02@regionh.dk](about:blank) |
| Urvi Shukla MD; | [urvi.shukla@suhrc.siu.edu.in](about:blank) |
| Michelle S. Chew PhD; | [michelle.chew@liu.se](about:blank) |
| Subhal Dixit MD; | [subhaldixit@yahoo.com](about:blank) |
| Charlotte S. Ulrik PhD; | [Charlotte.Suppli.Ulrik@regionh.dk](about:blank) |
| Pravin R. Amin MD; | [pravinramin@gmail.com](about:blank) |
| Rajesh Chawla MD; | [drchawla@hotmail.com](about:blank) |
| Christian A. Wamberg MD; | [christian.aage.wamberg.02@regionh.dk](about:blank) |
| Mehul S. Shah MD; | [Mehul.S.Shah@rfhospital.org](about:blank) |
| Iben S. Darfelt MD; | [IBEDAR@rm.dk](about:blank) |
| Vibeke L. Jørgensen PhD; | [Vibeke.Lind.Joergensen@regionh.dk](about:blank) |
| Margit Smitt MD; | [margit.smitt.01@regionh.dk](about:blank) |
| Anders Granholm MD; | [anders.granholm@regionh.dk](about:blank) |
| Maj-Brit N. Kjær MSc (Health); | [Maj-Brit.Noerregaard.Kjaer@regionh.dk](about:blank) |
| Morten H. Møller PhD; | [Morten.Hylander.Moeller@regionh.dk](about:blank) |
| Tine S. Meyhoff MD; | [Tine.Sylvest.Meyhoff@regionh.dk](about:blank) |
| Gitte K. Vesterlund MSc (Health); | [Gitte.Kingo.Vesterlund@regionh.dk](about:blank) |
| Naomi E. Hammond PhD;\* | [nhammond@georgeinstitute.org.au](about:blank) |
| Sharon Micallef BN; | [smicallef@georgeinstitute.org.au](about:blank) |
| Abhinav Bassi PT; | [abassi@georgeinstitute.org.in](about:blank) |
| Oommen John MD, MBA;\* | [ojohn@georgeinstitute.org.in](about:blank) |
| Anubhuti Jha MD; | [AJha@georgeinstitute.org](about:blank) |
| Maria Cronhjort PhD; | [maria.cronhjort@sll.se](about:blank) |
| Stephan M. Jakob PhD; | [stephan.jakob@insel.ch](about:blank) |
| Christian Gluud Dr Med Sc; | [christian.gluud@ctu.dk](about:blank) |
| Theis Lange PhD; | [thlan@sund.ku.dk](about:blank) |
| Vaijayanti Kadam MD; | [vaiju.nar@gmail.com](about:blank) |
| Klaus V. Marcussen MD; | [klvm@regionsjaelland.dk](about:blank) |
| Jacob Hollenberg PhD; | [jacob.hollenberg@sll.se](about:blank) |
| Anders Hedman MD; | [anders.hedman@sll.se](about:blank) |
| Henrik Nielsen DMSci; | [henrik.nielsen@rn.dk](about:blank) |
| Olav L. Schjørring PhD; | [o.schjoerring@rn.dk](about:blank) |
| Marie Q. Jensen BSc; | [marie.qvist.jensen@regionh.dk](about:blank) |
| Jens W. Leistner BSc; | [jens.wolfgang.leistner@regionh.dk](about:blank) |
| Trine B. Jonassen BSC; | [trine.bak.jonassen.03@regionh.dk](about:blank) |
| Camilla M. Kristensen BSc; | [camilla.meno.kristensen.03@regionh.dk](about:blank) |
| Esben C. Clapp BSc; | [esben.peter.christensen.clapp.01@regionh.dk](about:blank) |
| Carl J. S. Hjortsø BSc; | [carl.johan.steensen.hjortsoe.01@regionh.dk](about:blank) |
| Thomas S. Jensen MD; | [thomas.steen.jensen@regionh.dk](about:blank) |
| Liv S. Halstad BSc; | [liv.sanggaard.halstad@regionh.dk](about:blank) |
| Emilie R. B. Bak BSc; | [emilie.rose.bowman.bak.03@regionh.dk](about:blank) |
| Reem Zaabalawi BSc; | [reem\_zaabalawi@hotmail.com](about:blank) |
| Matias Metcalf-Clausen BSc; | [matiasmcdk@gmail.com](about:blank) |
| Suhayb Abdi BSc; | [suhayb.abdi@regionh.dk](about:blank) |
| Emma V. Hatley BSc; | [emma.victoria.hatley@regionh.dk](about:blank) |
| Tobias S. Aksnes BSc; | [tobiasaksnes@hotmail.com](about:blank) |
| Emil Gleipner-Andersen BSc; | [dgs771@alumni.ku.dk](about:blank) |
| A. Felix Alarcón BSc; | [felix.irfan@stud.ki.se](about:blank) |
| Gabriel Yamin BSc; | [gabriel.ymn@gmail.com](about:blank) |
| Adam Heymowski BSc; | [adam.heymowski@stud.ki.se](about:blank) |
| Anton Berggren BSc; | [anton.berggren@stud.ki.se](about:blank) |
| Kirstine la Cour BSc; | [klac@regionsjaelland.dk](about:blank) |
| Sarah Weihe BSc; | [sarwe@regionsjaelland.dk](about:blank) |
| Alison H. Pind BSc; | [alipi@regionsjaelland.dk](about:blank) |
| Janus Engstrøm BSc; | [janus.engstroem@ctu.dk](about:blank) |
| Vivekanand Jha PhD;\* | [vjha@georgeinstitute.org.in](about:blank) |
| Balasubramanian Venkatesh PhD;\* | [bvenkatesh@georgeinstitute.org.au](about:blank) |
| Anders Perner PhD | [Anders.Perner@regionh.dk](about:blank) |